Active Surveillance or Active Treatment in Localized Prostate Cancer?

被引:18
作者
Weissbach, Lothar [1 ]
Altwein, Jens [2 ]
机构
[1] Euromedclin Furth, D-90763 Furth, Germany
[2] Munchen Bogenhausen GmbH, Chirurg Klin, Munich, Germany
来源
DEUTSCHES ARZTEBLATT INTERNATIONAL | 2009年 / 106卷 / 22期
关键词
prostate cancer; prostatectomy; surveillance; treatment; PSA test; EXPECTANT MANAGEMENT; RADIATION-THERAPY; RISK-ASSESSMENT; ANTIGEN; MEN; INTERVENTION;
D O I
10.3238/arztebl.2009.0371
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: At present, one in six men over age 50 carries the diagnosis of prostate cancer, but only one in 33 will die of the disease. In view of these facts, conservative strategies such as active surveillance (AS) are important in the management of prostate cancer. Methods: To obtain information on active surveillance, the Medline database was searched from January 2002 to April 2008 for the terms "prostate cancer" OR "prostatic neoplasms," AND " active surveillance" OR " expectant management". In addition a manual search was performed in the reference lists of relevant publications on the treatment of prostate cancer and on active surveillance. Results: 88 relevant publications about active surveillance were found. The studies varied in methodological quality but consistently showed low rates of tumor progression and high rates of tumor-specific survival with active surveillance (99% to 100%). All 7 guidelines on the treatment of prostate cancer that have been published since 2006 list active surveillance in their recommendations as a therapeutic option for prostate cancer if there is a low risk of progression. In fact, the National Institute of Clinical Excellence (U. K.) recommends the active surveillance exclusively as the treatment strategy for such cases. Conclusions: The guideline recommendations reflect a changed attitude toward the treatment of prostate cancer in the light of the early detection of these tumors and the data now available regarding active surveillance. A corresponding change in actual medical practice would be desirable. The treatment of prostate cancer should always be adapted to the individual needs of the patient, and risky treatments should only be used when absolutely necessary. Dtsch Arztebl Int 2009; 106(22): 371-6 DOI: 10.3238/arztebl. 2009.0371
引用
收藏
页码:371 / I
页数:7
相关论文
共 31 条
[1]  
ALLAF ME, 2005, AUA UPDATE SERIES, V24, P2
[2]  
*AM UR ASS, GUID PROST CANC
[3]   Prostate cancer management: (1) an update on localised disease [J].
Bott, SRJ ;
Birtle, AJ ;
Taylor, CJ ;
Kirby, RS .
POSTGRADUATE MEDICAL JOURNAL, 2003, 79 (936) :575-580
[4]   EXPECTANT MANAGEMENT AND THE NATURAL-HISTORY OF LOCALIZED PROSTATE-CANCER [J].
CATALONA, WJ .
JOURNAL OF UROLOGY, 1994, 152 (05) :1751-1752
[5]  
Chen Weng-Ming, 2003, J Chin Med Assoc, V66, P236
[6]   Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression [J].
Choo, R ;
Klotz, L ;
Danjoux, C ;
Morton, GC ;
DeBoer, G ;
Szumacher, E ;
Fleshner, N ;
Bunting, P ;
Hruby, G .
JOURNAL OF UROLOGY, 2002, 167 (04) :1664-1669
[7]   Contemporary trends in low risk prostate cancer: Risk assessment and treatment [J].
Cooperberg, Matthew R. ;
Broering, Jeannette M. ;
Kantoff, Philip W. ;
Carroll, Peter R. .
JOURNAL OF UROLOGY, 2007, 178 (03) :S14-S19
[8]   The University of California, San Francisco cancer of the prostate risk assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy [J].
Cooperberg, MR ;
Pasta, DJ ;
Elkin, EP ;
Litwin, MS ;
Latini, DM ;
DuChane, J ;
Carroll, PR .
JOURNAL OF UROLOGY, 2005, 173 (06) :1938-1942
[9]   The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national disease registry [J].
Cooperberg, MR ;
Broering, JM ;
Litwin, MS ;
Lubeck, DP ;
Mehta, SS ;
Henning, JM ;
Carroll, PR .
JOURNAL OF UROLOGY, 2004, 171 (04) :1393-1401
[10]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974